 BOSTON--BUSINESS WIRE--Astria Therapeutics, Inc. NASDAQ:ATXS, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema HAE, today announced that the Company will be participating in two upcoming investor conferences: Oppenheimers 32nd Annual Healthcare Conference: On March 17, 2022 at 12:40pm ET, Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215. Guggenheim Healthcare Talks 